MedTrace Logo

723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover

NCT00972504 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-08-02

Study results available
· View outcomes & findings →

Summary

This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

DRUG

GSK835726 10mg

GSK835726 10mg tablet

DRUG

GSK1004723 1000mcg

GSK1004723 1000mcg nasal spray solution

DRUG

Cetirizine 10mg

Cetirizine 10mg active comparator

DRUG

placebo

placebo to match actives

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-01
Primary Completion
2009-08-01
Completion
2009-08-14

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00972504 on ClinicalTrials.gov